EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis

Daniel Kraemmer iD, Cihan Ay iD, Judit Rejtő, Georg Heinze, Peter Quehenberger, Ingrid Pabinger iD, Oliver Königsbrügge

Haemophilia · 2025-09 · 31 (5) · 1092-1102

DOI: 10.1111/hae.70085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 17.07.2025. Verfasst von Daniel Kraemmer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Factor VIII, Hemophilia A. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Emicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII‐equivalent activity (FVIIIeq) of emicizumab remains unknown.

Objectives

To estimate FVIIIeq of emicizumab using global assays of haemostasis. Patients/Methods We sampled plasma from (1) PWHA of all severities and therapeutic regimens and (2) persons with severe haemophilia A on emicizumab. Thrombin generation assay (TGA) and clot formation and lysis assay (CLA) were measured by commercially available (Technothrombin, Technoclone) and turbidimetric assays, respectively. FVIII was measured by a chromogenic (CSA) and emicizumab by a modified one‐stage assay (OSA). Using principal components (PC) or individual parameters as dependent and independent variables in linear regression with (1) FVIII and (2) emicizumab levels, respectively, we estimated FVIIIeq (95% CI) of emicizumab.

Results

We collected 253 samples from 110 PWHA and 41 samples from nine individuals on emicizumab prophylaxis. TGA parameters of emicizumab‐treated subjects clustered distinctly, with no correlation amongst samples with only endo‐/exogenous FVIII. Consequently, FVIIIeq varied substantially between parameters: Using individual TGA parameters, endogenous thrombin potential (ETP) and thrombin peak resulted in conversion factors of 0.85 (0.60–1.24) and 0.25 (0.15–0.37) IU/dL FVIIIeq per µg/mL emicizumab, respectively. CLA parameters showed broader overlap, with an FVIIIeq estimate of 0.82 (0.44–1.38).

Conclusion

Distinct clustering of emicizumab and FVIII samples in TGA leads to conflicting FVIIIeq estimates between parameters, highlighting systematic limitations and questioning their clinical usefulness. A, possibly conservative, FVIIIeq conversion factor estimate as determined by the thrombin peak could range from 0.15 to 0.37.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntibodies, Monoclonal, HumanizedFactor VIIIHemophilia AHemostasisHumansMaleAdultThrombinBlood Coagulation TestsMiddle Aged

Stichwörter der Autor:innen

antibodiesbispecificfactor VIIIfibrinolysishaemophiliathrombin

Substanzen

emicizumabAntibodies, BispecificAntibodies, Monoclonal, HumanizedFactor VIIIThrombin

Autor:innen und Institutionen

  • Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Institute of Clinical Biometrics, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.
  • Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Daniel Kraemmer, Cihan Ay, Ingrid Pabinger

Zitieren

APA

Kraemmer, D., Ay, C., Rejtő, J., Heinze, G., Quehenberger, P., Pabinger, I., & Königsbrügge, O. (2025). Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis. Haemophilia, 31(5), 1092-1102. https://doi.org/10.1111/hae.70085

Vancouver

Kraemmer D, Ay C, Rejtő J, Heinze G, Quehenberger P, Pabinger I, et al. Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis. Haemophilia. 2025;31(5):1092-1102. doi:10.1111/hae.70085

BibTeX
@article{Kraemmer2025,
  author = {Kraemmer, Daniel and Ay, Cihan and Rejtő, Judit and Heinze, Georg and Quehenberger, Peter and Pabinger, Ingrid and Königsbrügge, Oliver},
  title = {Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis},
  journal = {Haemophilia},
  year = {2025},
  volume = {31},
  number = {5},
  pages = {1092--1102},
  doi = {10.1111/hae.70085}
}
Kostenlos starten →